FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037211050> ?p ?o ?g. }

• W3037211050 endingPage "316" @default.
• W3037211050 startingPage "312" @default.
• W3037211050 abstract "Background Blood loss and transfusions have been highlighted as a significant predictor of postoperative morbidity. Tranexamic acid (TXA) has been shown to decrease blood loss and transfusion in shoulder arthroplasty. However, the utility of topical thrombin in total shoulder arthroplasty (TSA) is unknown. The purpose of this study was to assess the utility of topical thrombin in TSA and compare the effectiveness of topical thrombin to intravenous (IV) TXA. Methods An institutional database was used to query shoulder arthroplasty patients from January 2017 to July 2019. Patients undergoing TSA were identified with CPT (Current Procedural Terminology) code (23742). After excluding reverse shoulder arthroplasty, arthroplasty for fracture or revision, the study groups were stratified based on intervention with IV TXA, topical thrombin, or neither. Patient demographics, American Society of Anesthesiologists (ASA) class, baseline coagulopathy, preoperative and postoperative hemoglobin levels, operative time, transfusion, length of stay, and 90-day readmission for each treatment group was obtained. Results A total of 283 TSA cases were included for final analysis. There was no statistically significant difference in the baseline characteristics with age, body mass index, or ASA class. The postoperative hemoglobin level (mg/dL) was higher in the group that received either IV TXA or thrombin compared with no hemostatic agents (P = .001). Calculated blood loss in TSA was significantly higher in the group without hemostatic agents, 369.8 mL (standard deviation [SD] 59.5), compared with IV TXA or topical thrombin, 344.3 mL (SD 67.1) and 342.9 mL (SD 65.6) (P = .03). Operative time was highest in the group that received no hemostatic agents, 2.3 hours (SD 0.6) (P = .01). The transfusion rate for TSA treated with IV TXA or topical thrombin was equivalent (2.2%) but significantly lower than the no intervention group (12%) (P = .01). The odds ratio for transfusion with IV TXA was 0.16 (95% confidence interval [CI] 0.07-0.40, P = .001) and for topical thrombin, 0.1 (95% CI 0.02-0.42, P = .02). Conclusion Topical thrombin is an effective adjunct to reduce blood loss and transfusion risk after TSA and a reasonable intraoperative alternative for TXA for patients with contraindication to IV TXA. Blood loss and transfusions have been highlighted as a significant predictor of postoperative morbidity. Tranexamic acid (TXA) has been shown to decrease blood loss and transfusion in shoulder arthroplasty. However, the utility of topical thrombin in total shoulder arthroplasty (TSA) is unknown. The purpose of this study was to assess the utility of topical thrombin in TSA and compare the effectiveness of topical thrombin to intravenous (IV) TXA. An institutional database was used to query shoulder arthroplasty patients from January 2017 to July 2019. Patients undergoing TSA were identified with CPT (Current Procedural Terminology) code (23742). After excluding reverse shoulder arthroplasty, arthroplasty for fracture or revision, the study groups were stratified based on intervention with IV TXA, topical thrombin, or neither. Patient demographics, American Society of Anesthesiologists (ASA) class, baseline coagulopathy, preoperative and postoperative hemoglobin levels, operative time, transfusion, length of stay, and 90-day readmission for each treatment group was obtained. A total of 283 TSA cases were included for final analysis. There was no statistically significant difference in the baseline characteristics with age, body mass index, or ASA class. The postoperative hemoglobin level (mg/dL) was higher in the group that received either IV TXA or thrombin compared with no hemostatic agents (P = .001). Calculated blood loss in TSA was significantly higher in the group without hemostatic agents, 369.8 mL (standard deviation [SD] 59.5), compared with IV TXA or topical thrombin, 344.3 mL (SD 67.1) and 342.9 mL (SD 65.6) (P = .03). Operative time was highest in the group that received no hemostatic agents, 2.3 hours (SD 0.6) (P = .01). The transfusion rate for TSA treated with IV TXA or topical thrombin was equivalent (2.2%) but significantly lower than the no intervention group (12%) (P = .01). The odds ratio for transfusion with IV TXA was 0.16 (95% confidence interval [CI] 0.07-0.40, P = .001) and for topical thrombin, 0.1 (95% CI 0.02-0.42, P = .02). Topical thrombin is an effective adjunct to reduce blood loss and transfusion risk after TSA and a reasonable intraoperative alternative for TXA for patients with contraindication to IV TXA." @default.
• W3037211050 created "2020-07-02" @default.
• W3037211050 creator A5008059549 @default.
• W3037211050 creator A5017096394 @default.
• W3037211050 creator A5036964622 @default.
• W3037211050 creator A5067531725 @default.
• W3037211050 creator A5078476304 @default.
• W3037211050 creator A5085729463 @default.
• W3037211050 date "2021-02-01" @default.
• W3037211050 modified "2023-10-18" @default.
• W3037211050 title "Intravenous tranexamic acid vs. topical thrombin in total shoulder arthroplasty: a comparative study" @default.
• W3037211050 cites W1956279162 @default.
• W3037211050 cites W1958535145 @default.
• W3037211050 cites W1976310234 @default.
• W3037211050 cites W1987511048 @default.
• W3037211050 cites W2040521618 @default.
• W3037211050 cites W2051300945 @default.
• W3037211050 cites W2058651635 @default.
• W3037211050 cites W2115971566 @default.
• W3037211050 cites W2184190511 @default.
• W3037211050 cites W2338880694 @default.
• W3037211050 cites W2345224086 @default.
• W3037211050 cites W2585904185 @default.
• W3037211050 cites W2742150391 @default.
• W3037211050 cites W2754682189 @default.
• W3037211050 cites W2785893356 @default.
• W3037211050 cites W2785963611 @default.
• W3037211050 cites W2800414435 @default.
• W3037211050 cites W2898548428 @default.
• W3037211050 cites W2935936353 @default.
• W3037211050 cites W2939950789 @default.
• W3037211050 cites W2947905084 @default.
• W3037211050 cites W2985357865 @default.
• W3037211050 doi "https://doi.org/10.1016/j.jse.2020.05.039" @default.
• W3037211050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32592848" @default.
• W3037211050 hasPublicationYear "2021" @default.
• W3037211050 type Work @default.
• W3037211050 sameAs 3037211050 @default.
• W3037211050 citedByCount "5" @default.
• W3037211050 countsByYear W30372110502021 @default.
• W3037211050 countsByYear W30372110502022 @default.
• W3037211050 countsByYear W30372110502023 @default.
• W3037211050 crossrefType "journal-article" @default.
• W3037211050 hasAuthorship W3037211050A5008059549 @default.
• W3037211050 hasAuthorship W3037211050A5017096394 @default.
• W3037211050 hasAuthorship W3037211050A5036964622 @default.
• W3037211050 hasAuthorship W3037211050A5067531725 @default.
• W3037211050 hasAuthorship W3037211050A5078476304 @default.
• W3037211050 hasAuthorship W3037211050A5085729463 @default.
• W3037211050 hasConcept C126322002 @default.
• W3037211050 hasConcept C141071460 @default.
• W3037211050 hasConcept C2777292125 @default.
• W3037211050 hasConcept C2778336525 @default.
• W3037211050 hasConcept C2778917026 @default.
• W3037211050 hasConcept C2779637338 @default.
• W3037211050 hasConcept C2780221984 @default.
• W3037211050 hasConcept C2991743468 @default.
• W3037211050 hasConcept C42219234 @default.
• W3037211050 hasConcept C71924100 @default.
• W3037211050 hasConcept C89560881 @default.
• W3037211050 hasConceptScore W3037211050C126322002 @default.
• W3037211050 hasConceptScore W3037211050C141071460 @default.
• W3037211050 hasConceptScore W3037211050C2777292125 @default.
• W3037211050 hasConceptScore W3037211050C2778336525 @default.
• W3037211050 hasConceptScore W3037211050C2778917026 @default.
• W3037211050 hasConceptScore W3037211050C2779637338 @default.
• W3037211050 hasConceptScore W3037211050C2780221984 @default.
• W3037211050 hasConceptScore W3037211050C2991743468 @default.
• W3037211050 hasConceptScore W3037211050C42219234 @default.
• W3037211050 hasConceptScore W3037211050C71924100 @default.
• W3037211050 hasConceptScore W3037211050C89560881 @default.
• W3037211050 hasIssue "2" @default.
• W3037211050 hasLocation W30372110501 @default.
• W3037211050 hasOpenAccess W3037211050 @default.
• W3037211050 hasPrimaryLocation W30372110501 @default.
• W3037211050 hasRelatedWork W1999291976 @default.
• W3037211050 hasRelatedWork W2116030324 @default.
• W3037211050 hasRelatedWork W2317612395 @default.
• W3037211050 hasRelatedWork W2406666456 @default.
• W3037211050 hasRelatedWork W3035080894 @default.
• W3037211050 hasRelatedWork W3182087953 @default.
• W3037211050 hasRelatedWork W4226535647 @default.
• W3037211050 hasRelatedWork W4233116497 @default.
• W3037211050 hasRelatedWork W4233410146 @default.
• W3037211050 hasRelatedWork W4313334971 @default.
• W3037211050 hasVolume "30" @default.
• W3037211050 isParatext "false" @default.
• W3037211050 isRetracted "false" @default.
• W3037211050 magId "3037211050" @default.
• W3037211050 workType "article" @default.